Upregulation of microRNA 344a-3p is involved in curcumin induced apoptosis in RT4 schwannoma cells
- 88 Downloads
Schwannoma arising from peripheral nervous sheaths is a benign tumor.
To evaluate cell cytotoxicity, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction and terminal deoxynucleotidyltransferase UTP nick-end labeling (TUNEL) assays were used. A microRNA (miRNA) array was used to identify the miRNAs involved in curcumin-induced apoptosis. To examine miRNA expression, quantitative RT-PCR was used.
In this study, curcumin exerted cellular cytotoxicity against RT4 schwannoma cells, with an increase in TUNEL-positive cells. Curcumin also activated the expression of apoptotic proteins, such as polyADP ribose polymerase, caspase-3, and caspase-9. The miRNA array revealed that seven miRNAs (miRNA 350, miRNA 17-2-3p, let 7e-3p, miRNA1224, miRNA 466b-1-3p, miRNA 18a-5p, and miRNA 322-5p) were downregulated following treatment with both 10 and 20 μM curcumin in RT4 cells, while four miRNAs (miRNA122-5p, miRNA 3473, miRNA182, and miRNA344a-3p) were upregulated. Interestingly, transfection with a miRNA 344a-3p mimic downregulated the mRNA expression of Bcl2 and upregulated that of Bax, Curcumin treatment in RT 4 cells also reduced the mRNA expression of Bcl2 and enhanced expression of Bax, Overexpression of miRNA344a-3p mimic combined with curcumin treatment activated the expression of apoptotic proteins, including procaspase-9 and cleaved caspase-3 while inhibition of miRNA 344a-3p using miR344a-3p inhibitor repressed cleaved caspase-3 and -9 in curcumin treated RT-4 cells compared to control.
Our findings demonstrate that curcumin induces apoptosis in schwannoma cells via miRNA 344a-3p. Thus, curcumin may serve as a potent therapeutic agent for the treatment of schwannoma.
KeywordsCurcumin MicroRNA Schwannoma RT4
heat shock protein
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling
Schwannoma arising from peripheral nervous sheaths originates from the neuroectoderm and myelin-forming Schwann cells . Schwannomas originate from the vestibular nerve and are accompanied by hearing loss and neurological disorders [2, 3, 4]. Neurofibromatosis 2 (NF2) results from loss of the NF2 gene, which encodes the Merlin protein . Furthermore, NF2 mutations increase the risk of several tumors, such as ependymomas, meningiomas, and schwannomas . Thus, there is an urgent need to identify anti-cancer drugs for the treatment of ependymomas, meningiomas, and schwannomas caused by NF2 gene mutations.
Curcumin, derived from the spice turmeric (Curcuma longa), is a non-flavonoid polyphenol. Curcumin has multiple biological activities, such as anti-inflammatory activity , anti-bacterial action , and anti-oxidant properties . Curcumin also exhibits neuroprotective effects in Huntington’s  and Alzheimer’s  diseases. Although curcumin is well-known for its anti-tumor effects in several cancer cells , its anti-cancer mechanism in schwannoma remains unknown.
MicroRNAs (miRNAs/miRs) are small, non-coding RNAs that modulate gene expression such as mRNA degradation by binding to the 3′-untranslated region . miRNAs have been suggested as potential drug targets in various cancer models [14, 15]. For example, anti-miRNA 203 suppressed the breast cancer proliferation and stemness by targeting cytokine signaling 3 (SOCS3)  and miRNA-212 inhibited nonsmall lung cancer cell migration and invasion by modulating ubiquitin-specific protease-9-X-linked (USP9X) . MiR 1 inhibited gastric cancer cell growth by regulating angiogenesis related growth factor such as endothelial growth factor A (VEGF-A) and endothelin 1 (EDN1) . Although the miRNAs act as tumor suppressors in several cancer cells, such as prostate cancer  and osteosarcoma , they have not been fully investigated in schwannoma cells. Thus, in this study, the underlying anti-cancer mechanism of curcumin was elucidated in RT4 schwannoma cells in association with the upregulation of miRNA 344a-3p following a miRNA array.
Materials and methods
RT4-D6P2T, a schwannoma cell line resulting from an N-ethyl-N-nitrosourea (ENU)-induced rat peripheral neurotumor (American Type Culture Collection, Manassas, VA, USA) (ATCC CRL-2768 ATCC® Number: CRL-2768), was cultured in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO/Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 2 μM l-glutamine, and penicillin/streptomycin in 5% CO2.
Curcumin and Taxol were purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO).
Cell viability assay
An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay (Sigma-Aldrich) was performed to determine cell viability. RT4 schwannoma cells were seeded onto a 96-well plate at a concentration of 2.5 × 104 cells/µl/well. Following cell attachment, RT4 schwannoma cells were treated with various concentrations (0, 5, 10, 20, 40, and 80 μM) of curcumin or Taxol for 24 h, followed by incubation with 20 µl MTT (5 mg/ml) for 4 h. To visualize living cells, DMSO (200 µl) was added to each well, and the absorbance value of the wells was measured at 490 nm on a spectrophotometer.
Quantitative RT-PCR (qPCR)
Curcumin was added to RT4 schwannoma cells for 24 h and total RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed with a Reverse Transcription Kit (Promega, Madison WI, USA). Quantitative PCR (qPCR) was performed on an ABI 7500 Real-time PCR Instrument (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s protocol. The mRNA level of each target gene was normalized to that of 18S. The primers used in this study were as follows:
Bcl2 forward; 5′-CTGGTGGACAACATCGCTCTG-3′, reverse; 5′-GGTCTGCTGACCTCACTTGTG-3′, Bax forward; 5′-TTCATCCAGGATCGAGCAGA-3′, reverse; 5′-GCAAAGTAGAAGGCAACG-3′, and 18S forward; 5′-AGTCCCTGCCCTTTGTACACA-3′, reverse: 5′-GATCCGAGGGCCTCACTAAA-3′.
Western blot analysis
RT4 schwannoma cells (2.5 × 105) were treated with curcumin for 24 h and washed with cold phosphate-buffered saline (PBS). After centrifugation, radioimmunoprecipitation assay buffer (50 mM Tris–HCl [pH 7.5], 150 mM sodium chloride, 1% Triton X-100, 0.1% SDS, 2 mM EDTA, and 0.5% sodium deoxycholate) was added to RT4 schwannoma cells, incubated for 30 min on ice, and centrifuged at 14,000×g for 30 min at 4 °C. Protein contents of the supernatants were measured using the DC Protein Assay Kit II (Bio-Rad, Hercules, CA, USA) and then separated on 10% NuPAGE Bis–Tris gels (Invitrogen) and electro-transferred onto Hybond enhanced chemiluminescence (ECL) transfer membranes (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). After blocking the membranes in 5% nonfat dry milk, the membrane was immunoblotted with antibodies against cleaved caspase-3 (1:1000, Cell Signaling Technology, Danvers, MA, USA, cat-9664), caspase-9 (1:1000, Cell Signaling Technology, cat-9508), cleaved caspase-9 (1:1000, Cell Signaling Technology, cat-7237), PARP (1:1000, Cell Signaling Technology, cat-9532), and β-actin (1:1000, Cell Signaling Technology, cat-3700). After washing, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody, and ECL (GE Healthcare Bio-Sciences) was used to visualize the protein.
To observe cell death in curcumin-treated RT4 cells, the DeadEnd™ Fluorometric Terminal Deoxynucleotidyl Transferase-mediated dUTP-biotin Nick-end Labeling (TUNEL) system kit was used according to the manufacturer’s instructions (Sigma-Aldrich). In brief, curcumin-treated RT4 schwannoma cells were washed with cold PBS and fixed in 4% paraformaldehyde for 30 min. After washing with PBS, RT4 cells were fixed in a permeabilization solution (0.1% Triton X-100 and 0.1% sodium citrate) and incubated with the TUNEL assay mixture for 60 min. To visualize TUNEL-stained cells, the FLUOVIEW FV10i confocal microscope (Olympus, Tokyo, Japan) was used.
Total RNA from curcumin-treated RT4 schwannoma cells was extracted with TRIZOL reagent (Invitrogen) according to the manufacturer’s protocol. The miRNA array was performed according to standard protocols as previously described .
Functional analysis of miRNAs
Functional classification of miRNAs from the miRNA array was categorized by the Gene Ontology database provided by miRWalk 2.0.
RT4 schwannoma cells were transfected with the miRNA 344a-3p miRNA mimic or 344a-3p inhibitor (rno-miRNA 344a-3p; MIMAT0000592; ACAGUCAGGCUUUGGCUAGAUCA) (Genolution, Seoul, South Korea) using Lipofectamine (Invitrogen) according to the manufacturer’s protocol. At 24 h after transfection, curcumin was treated for 24 h and then cells were collected for further experiments.
All experiments were performed at least three times. Data are presented as the mean ± standard deviation of triplicate samples using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). The t test was used to determine statistical significance.
Curcumin is a well-known bioactive compound due to its efficacy and low toxicity in various cancers . Angelo et al.  showed that the combined treatment of curcumin with a heat shock protein (Hsp) inhibitor inhibited the proliferation of a human schwannoma cell line (HEI-193) harboring an NF2 mutation. Hsp 70 and Hsp 90, which are important players in cancer growth, were identified as binding partners of curcumin in human schwannoma cells . Similarly, curcumin treatment in RT4 schwannoma cells exerted cytotoxicity and activated caspase-3, caspase-9, and PARP, all of which are apoptotic proteins. Therefore, our data suggest that curcumin may serve as a potent therapeutic for the treatment of schwannoma.
miRNAs, as small, non-coding RNAs, have multiple biological functions in apoptosis, angiogenesis, growth, and differentiation [27, 28, 29]. miRNA expression from schwannomas from 16 patients was deregulated . Previous studies have shown that miRNA-7 and miRNA-29a suppressed the growth of schwannoma [31, 32], while miRNA-21 enhanced the proliferation of schwannoma . In addition, there is evidence that miRNAs are one of the key targets of the anti-cancer effects of curcumin [22, 34, 35]. For example, curcumin suppressed cell growth via miRNA-7 expression in pancreatic cancer  or via the upregulation of miRNA 378 in glioblastoma . Furthermore, curcumin inhibited the cell proliferation of laryngeal cancer cells via miR15a by targeting Bcl2 and PI3K/Akt  and induced apoptosis via the upregulation of miR192-5p by suppressing PI3K/Akt in human non-small cell lung cancer cells . In this study, the microarray analysis from curcumin-treated RT4 schwannoma cells revealed that 11 miRNAs from both 10 and 20 μM curcumin-treated cells were differentially expressed compared to the control group. miRNA 122-5p, miRNA 344a-3p, miRNA 3473, and miRNA 182 were upregulated following treatment with 10 and 20 μM curcumin in RT4 schwannoma cells. Functional analysis indicated that miRNAs from curcumin-treated RT4 cells belong to several functional categories, such as aging (5.77%), angiogenesis (3.57%), apoptosis (7.69%), cell cycle (6.38%), cell differentiation (7.41%), cell migration (6.00%), cell proliferation (8.16%), and the immune response (6.25%). Of note, the overexpression of miRNA 344a-3p by using the mimic combined with curcumin treatment in RT4 cells activated the expression of apoptotic markers, such as caspase-3, and caspase-9 compared to the control, suggesting that miRNA344a-3p plays an important role in curcumin-induced apoptosis in RT4 schwannoma cells.
In conclusion, curcumin was cytotoxic to RT4 schwannoma cells and enhanced the expression of apoptotic proteins such as PARP, caspase-3, and caspase-9, as well as the number of TUNEL-positive cells. Notably, the miRNA array revealed that curcumin-treated RT4 schwannoma cells expressed different miRNAs. The overexpression of miRNA344a-3p using the mimic combined with curcumin treatment in RT4 cells enhanced cell death. Thus, the results of this study suggest that curcumin could be used as a potential treatment for schwannoma by targeting miRNA 344a-3p.
ES: design paper, data manuscript writing, KB and YN: perform experiments, HP: manuscript writing. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
Please contact author for data requests.
Consent for publication
All authors approved the publication of this manuscript.
Ethics approval and consent to participate
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2018R1D1A1B07043762) and by the National Research Foundation of Korea (NRF) Grant funded Korea government (MSIT) (No. 2016R1A5A2007009).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Fuller GN. The WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med. 2008;132:906.Google Scholar
- 2.Celis-Aguilar E, Lassaletta L, Torres-Martin M, et al. The molecular biology of vestibular schwannomas and its association with hearing loss: a review. Genet Res Int. 2012;2012:856157.Google Scholar
- 24.Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008;52(Suppl 1):S103–27.Google Scholar
- 27.Zhou X, Chen J, Xiao Q, et al. MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. Biosci Rep. 2018;38:1017.Google Scholar
- 29.Wang G, Fang X, Han M, et al. MicroRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2. Int J Mol Med. 2018;41:1740–8.Google Scholar
- 33.Cioffi JA, Yue WY, Mendolia-Loffredo S, et al. MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival. Otol Neurotol. 2010;31:1455–62.Google Scholar
- 37.Li W, Yang W, Liu Y, et al. MicroRNA-378 enhances inhibitory effect of curcumin on glioblastoma. Oncotarget. 2017;8:73938–46.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.